Number of pages: 100 | Report Format: PDF | Published date: March 31, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
Report Attribute |
Details |
Market Size Value in 2022 |
US$ 2.79 billion |
Revenue Forecast in 2031 |
US$ 6.69 billion |
CAGR |
10.20% |
Base Year For Estimation |
2022 |
Forecast Period |
2023-2031 |
Historical Year |
2021 |
Segments Covered |
Treatment, End User, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global brain metastasis therapeutics market was valued at US$ 2.79 billion in 2022 and is expected to register a revenue CAGR of 10.20% to reach US$ 6.69 billion by 2031.
Market Fundamentals
Brain metastasis arises when cancer cells spread to the brain, causing damage. Brain metastases can result in the formation of one or more tumors in the brain. As metastatic brain tumors grow, they put pressure on and alter the functioning of surrounding brain tissue. Seizures, personality changes, memory loss, and headaches are some signs and symptoms of brain metastasis.
[45654]
Market Dynamics
The key factor increasing the global brain metastasis therapeutic market revenue share is the rising incidences of cancer. Brain metastasis is mostly caused by highly prevalent lung and breast cancer. Breastcancer.org stated in February 2023 that brain metastases exist in 10% to 15% of women with stage IV breast cancer. Those with more aggressive forms of breast cancer, such as HER2-positive or triple-negative breast cancer, typically have the highest chance of brain metastases. Breast cancer is more prone than many other tumors to spread to the brain, partly because the brain's hippocampus, hypothalamus, and amygdala contain high concentrations of estragon levels. Moreover, patients with lung cancer are also frequently developing brain metastasis. Roughly 25% of lung cancer patients have developed brain metastasis; the overall risk is about 50%, states American Lung Association in 2022. The rising prevalence of cancer and the growing demand for efficient therapies for brain metastasis is expected to fuel the market revenue growth for brain metastasis therapeutics during the forecast period. The market is expected to grow in revenue share during the forecast period due to technological developments, imaging, and targeted therapeutics. The most frequent causes of brain metastases are highly prevalent lung and breast malignancies; however, other diseases like melanoma and kidney cancer are also frequently linked to metastatic spread to the CNS. Advances in imaging technologies such as MRI and PET scans enable earlier detection of brain metastasis, increasing the demand for effective therapeutics.
Moreover, researching and marketing efficient treatments for brain metastasis are the main goals of many top players in brain metastasis. Companies are launching educational programs to increase public awareness of brain metastasis, its symptoms and signs, and the available treatments. This may contribute to a higher demand for efficient therapies. Pharmaceutical companies spend more on research and development to create better ways to treat brain metastases. Investments and collaboration by many top companies will also introduce innovative treatments of brain metastasis therapeutics. In addition, governments in many low-income nations are increasing funding for research and development activities on brain metastasis and expanding the geographic reach of leading companies in this field, making many brain metastasis therapies more widely available.
Research and developments on brain metastasis therapeutics are expected to increase the global brain metastasis therapeutics market. Personalized treatments for brain metastasis are a promising approach that aims to tailor treatment to an individual patient's specific characteristics, such as the type and location of their cancer, genetic mutations, and immune system status. This approach involves using advanced imaging techniques to create a 3D map of the brain and the metastatic tumors, allowing doctors to precisely target the cancer cells with radiation therapy while minimizing damage to healthy brain tissue. This personalized treatment has shown promising results in improving patient outcomes and quality of life. Moreover, deep learning (DL) and radiomics developments have a huge potential to lead precision medicine for treating patients with metastatic disease. Radiomics and DL can support clinical decision-making by assisting in correct diagnosis, identifying molecular markers, offering accurate prognoses, and tracking treatment response.
However, one of the major limiting factors for the brain metastasis therapeutics market is the lack of effective treatments that can cross the blood-brain barrier. The high cost of developing and manufacturing these treatments also poses a challenge to market revenue growth.
Market Ecosystem
The global brain metastasis therapeutic market is analyzed from three perspectives: treatment, end user, and region.
Brain Metastasis Therapeutics Market by Treatment
[89064]
Based on treatment, the global brain metastasis therapeutic market is segmented into immunotherapy, targeted therapy, and chemotherapy.
The chemotherapy segment dominates the global brain metastasis therapeutic market. Chemotherapy effectively treats brain metastasis, particularly with other treatments such as surgery and radiation therapy. However, the effectiveness of chemotherapy may vary depending on the type of cancer and the individual patient's response to treatment.
The targeted therapy segment has shown promising results in treating brain metastasis by targeting genetic mutations or proteins. It is expected to rise significantly in terms of revenue share during the forecast period by driving tumor growth. Additionally, research and developments on targeted therapy are introducing new advancements, such as combinations of targeted therapies for different brain metastases. Moreover, This approach can improve treatment outcomes and reduce side effects compared to traditional chemotherapy.
Recently, immunotherapy has shown promising results in treating brain metastasis by activating the immune system to target cancer cells in the brain. However, further research is needed to determine its long-term efficacy and potential side effects.
Brain Metastasis Therapeutics Market by End User
Based on end users, the global brain metastasis therapeutic market is segmented into cancer research, cancer hospitals, hospitals, clinics, and others.
The hospital segment accounts for most of the revenue share in the global brain metastasis therapeutic market. Brain metastasis is a common complication in patients at advanced cancer stages and can significantly impact their quality of life. Hospitals use various treatment options, including surgery, radiation therapy, and chemotherapy, to manage brain metastasis and improve patient outcomes. Moreover, the availability of skilled professionals and more advanced technologies in hospitals are driving the revenue growth of the hospital segment.
The cancer hospitals segment is expected to progress with a high revenue share in 2022. Brain metastasis treatment from cancer hospitals involves a multidisciplinary approach that may include surgery, radiation therapy, chemotherapy, and targeted therapy. These hospitals have specialized doctors and advanced technology teams to provide personalized treatment plans for patients with brain metastasis. Additionally, they offer supportive care services such as counseling, rehabilitation, and pain management to improve the quality of life for patients and their families.
Brain Metastasis Therapeutics Market by Region
Based on the region, the global Brain Metastasis Therapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominates the global brain metastasis therapeutic market with the largest revenue share. This large revenue share is attributed to the increasing prevalence of cancer and the rising demand for advanced treatment options. The presence of key market players and the development of innovative therapies also drive the market in terms of revenue share.
The brain metastasis therapeutics market in Europe is expected to experience significant revenue growth due to the increasing prevalence of osteoporosis and hip fractures among the aging population. Additionally, advancements in technology by many top players and the presence of a large patient pool. Moreover, in Europe, the high adoption of technologically advanced products drives the global brain metastasis therapeutics market.
During the forecast period, Asia Pacific is expected to show lucrative growth in terms of revenue share. This is attributed to the increasing patient pool. Rising healthcare expenditure in Asia Pacific has made advanced medical technologies more accessible to the population. The availability of better healthcare facilities and increased affordability of medical treatments due to favorable reimbursement plans are also driving the global brain metastasis therapeutics market in the Asia Pacific. Moreover, the region consists of many government-funded cancer hospitals, which increases the accessibility of treatment for brain metastasis in Asia Pacific. This increased awareness is expected to boost the demand for femoral nailing systems in the Asia Pacific.
Competitive Landscape for Brain Metastasis Therapeutics Market
The brain metastasis therapeutic market is highly competitive due to the presence of several established players and the emergence of new competitors. Factors such as technological advancements and strategic collaborations are expected to accelerate the competition in the market. Moreover, companies are increasingly looking for ways to increase their product portfolio through mergers and collaborations.
The prominent companies operating in the global brain metastasis therapeutic market are:
Strategic Developments in Brain Metastasis Therapeutics Market
The chemotherapy segment accounts for the largest revenue share in the global brain metastasis therapeutic market.
The global brain metastasis therapeutic market is expected to register a revenue CAGR of 10.20% during the forecast period.
AstraZeneca, plc, GlaxoSmithKline, plc, Eli Lilly & Company, and AngioChem Inc. are key players in the global brain metastasis therapeutic market.
The Asia Pacific region is expected to observe the highest global brain metastasis therapeutic market revenue growth during the forecast period.
The brain metastasis therapeutics market in the low- and middle-income is limited due to a lack of awareness, high cost, and lack of favorable reimbursement scenarios.
*Insights on financial performance are subject to the availability of information in the public domain